To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01785433 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Tiotropium HFA BAI 4.5 mcg
DRUG: Tiotropium HFA BAI 9.0 mcg
DRUG: SPIRIVA® HandiHaler® 18 mcg/day
DRUG: Spiriva® Respimat® 5 mcg/day

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.